

Intellectual Property advocacy in the fields of:

- IP Infrastructure
- IP Valuation
- M & A
- IP Policy
- Technology Transfer
- Innovation Research
- Patent Law
- Licensing
- Data Management
- Copyright
- Collaborations
- Balance for Rights & Obligations

For Private Circulation Only



Online Session
on
**COVID-19 Drug Candidates:
Understanding Patent Landscapes & Navigating Patent Barriers**

Monday, June 08, 2020
3:30 pm to 5:35 pm

Gopakumar Nair

Sridhya Ravi

Andriya Fernandes

Ginish George

Premnath Venugopalan

Vidula Walimbe

VENTURE CENTER

TechEx.in
Tech Transfer Hub

birac
NATIONAL BIOPHARMA MISSION

nbm
NATIONAL BIOPHARMA MISSION

TFORD-COVID19 INDIA
Powered by Venture Center & NCL Innovations, CSIR

The aim of the online session was to provide the IP enthusiasts and IP Managers an insight into the potential drug candidates for COVID-19 and their patent position with the help of Patent Landscapes, Relevant provisions in Indian Patent Law and selected global provisions and Patent Barriers. The online event was a success with participants from various fields.

Source: <http://www.techex.in/online-session-on-covid-19-drug-candidates/>

Intellectual Property advocacy in the fields of:

- IP Infrastructure
- IP Valuation
- M & A
- IP Policy
- Technology Transfer
- Innovation Research
- Patent Law
- Licensing
- Data Management
- Copyright
- Collaborations
- Balance for Rights & Obligations

For Private Circulation Only

TASK FORCE ON REPURPOSING OF DRUGS FOR COVID19

Charting the path for India

Latest Information On Key Drug Candidates For COVID-19 is available at <https://nclinnovations.org/covid19/resources/>

The information relates to Molecule Briefs with ongoing clinical trials, such as Remdesivir, Favipiravir and Molecule Briefs without any ongoing clinical trials such as Galidesivir and Ustekinumab amongst others. Information on Medicinal Herbs Brief is also available.

Experts rated different molecules and the journey ahead is available as

- **Heat map 1: Drug Candidate Readiness and Potential**
- **Heat map 2: Patent Position**
- **Heat map 3: Clinical Trials Reported**
- **Heat map 4: Indian manufacturers of drug candidates studied by TFORD**
- **Heat map 5: Selected medicinal herbs, status of CTs in India and selected major Indian manufacturers/ suppliers**

Intellectual Property advocacy in the fields of:

- IP Infrastructure
- IP Valuation
- IP Policy
- Technology Transfer
- Patent Law
- Licensing
- Copyright
- Collaborations
- M & A
- Innovation Research
- Data Management
- Balance for Rights & Obligations

For Private Circulation Only

Webinars by Dr. Gopakumar G. Nair

Vidya Vilas Education Trust's


Lords Universal College of Law

(Permanently Unaided, Affiliated to University of Mumbai; Recognised by BCI)
Recognised as Gujarati Linguistic Minority Institution
Topiwala Marg, Off Station Road, Goregaon West, Mumbai - 400 104

presents **WEBINAR** on

**THE THEORY AND PRACTICE OF THE LAWS
RELATING TO INTELLECTUAL PROPERTY RIGHTS**

KEYNOTE SPEAKER



Dr. Gopakumar Nair
Patent Attorney
Founder and CEO, Gopakumar Nair & Associates

Wednesday, 10th June 2020
Time - 4:00 pm onwards

Registration link: <http://link.universal.edu.in/participants1>
(Platform: Webex meeting- link will be shared soon)

Session followed by Q & A

Chief patron
Dr. Sameena Hasan
(L/C Principal)


Thakur Educational Trust's (Regd.)

THAKUR RAMNARAYAN COLLEGE OF LAW

S. V. Road, Dahisar (East), Mumbai - 400 068

LIVE WEBINAR

Patenting of pharmaceutical drugs in times of covid-19
[scopes and challenges]



Dr. Gopakumar G. Nair
PhD in Organic Chemistry.
Registered Patent & Trademark Attorney.
40 years Experience in Pharmaceutical & chemical industry.
Ex-chairman Pharma Panel of CHEMEXCIL (Export Promotion Council).
Author of large number of Scientific Technical Research & popular publication, Co-inventor of currently valid Patent no. IN188860 titles "Novel process preparation of 3 Chloropropiophenone" presently assigned to Sequent Scientific Ltd.

DATE: 2ND JUNE 2020, TUESDAY
TIME: 11:00 am TO 12:30 PM
LIVE ON CISCO WEBEX
GUEST SPEAKER : DR. GOPAKUMAR G. NAIR

DETAILS:

Date and time: JUNE 2ND 2020, TUESDAY, 11:00 am to 12:30 pm.

The webinar will be hosted on CISCO WEBEX AND LIVE ON YOUTUBE.

Participants will be muted and can ask question over the Q and A box.

Last date for registration is 1ST JUNE 2020. (Link will be provided).

E-certificate will be provided to the attendees.

Presided Over By Dr. AK. Singh (retired)

Intellectual Property advocacy in the fields of:

- IP Infrastructure
- IP Valuation
- M & A
- IP Policy
- Technology Transfer
- Innovation Research
- Patent Law
- Licensing
- Data Management
- Copyright
- Collaborations
- Balance for Rights & Obligations

For Private Circulation Only

Remdesivir, now part of Covid-19 therapy in Centre's new health protocol document

In the new set of protocols, the ministry has removed its earlier recommendation of using hydroxychloroquine in combination with azithromycin in severe cases and requiring ICU management.

Source: <https://www.hindustantimes.com/india-news/remdesivir-now-part-of-covid-19-therapy-in-centre-s-new-health-protocol-document/story-3uwZmP9qLB31YX57WgjryH.html>

India sets up first mobile COVID-testing lab

The laboratory can be deployed at remote and inaccessible areas in the country, where there is no such facility, even as the overall Covid-19 testing capacity has reached three lakh swab samples per day.

Source: <https://www.hindustantimes.com/india-news/india-sets-up-first-mobile-covid-testing-lab/story-YvtNiwZnoUJlo6nMHI0SAM.html>

"Major Breakthrough":

UK Trial Shows Dexamethasone Drug Saves 1 Of 3 Severe COVID Cases

The results, described as a "major breakthrough" by scientists leading the UK-led clinical trial known as RECOVERY, suggest the drug should immediately become standard care in patients treated in hospital with the pandemic disease, the researchers said.

Source: <https://www.ndtv.com/world-news/dexamethasone-coronavirus-drug-uk-trial-shows-dexamethasone-drug-saves-1-of-3-three-severe-covid-cases-2247276>

Coronavirus (Covid-19) vaccine status check:

Oxford vaccine to provide protection for a year; Moderna efficacy data by October

Source: <https://indianexpress.com/article/coronavirus/coronavirus-covid-19-vaccine-oxford-moderna-imperial-college-curevac-status-check-6461648/>

Six Indian companies applied to CDSCO for permission to manufacture, market

Remdesivir drug: Health Ministry

The Centre on Sunday said that six Indian companies -- Hetero, Cipla, BDR, Jubilant, Mylan and Dr Reddy's Labs -- have applied to Indian Drug Regulatory Agency, Central Drug Standard Control Organisation (CDSCO) for permission to manufacture and market the Remdesivir drug in India. The Health Ministry released an updated Clinical Management Protocol for COVID-19, in which the drug Remdesivir has been included as an "investigational therapy" only for restricted emergency use purposes.

Source: <https://www.timesnownews.com/health/article/six-indian-companies-applied-to-cdsco-for-permission-to-manufacture-market-remdesivir-drug-health-ministry/606482>